NeoGenomics’s data presentation at the ESMO Congress 2025

Image Credit: NeoGenomics

Announcement 

The neogenomics, inc the known provider of oncology diagnostic solutions that allow accuracy in medicine highlighted its presentation of assay-suitable data, involving the ongoing interventional therapy trials to put light on how its molecular residual disease (MRD) assay may prove beneficial to the pharmaceutical collaborators at the European society for medical oncology (ESMO) congress 2025, ibn berlin Germany on October 17-21. The neogenomics circulating tumour DNA (ctDNA) assay, RaDaR ST, is engineered to leverage and boost oncology drug development.

The data will further fuel the oncology treatment sector and provide new advancements in the same. Presentation’s acceptance from leading providers and healthcare companies will help the company to strengthen its position in the healthcare market. The assay holds potential to have a drug development solution with insights for the providers to consider and implement.

Assay specification

Building on the company’s well-developed molecular potential, the RaDaR ST assay implicates whole-exome sequencing data from the improved bioinformatics and tumour samples to generate patient-centric MRD panels. By accelerating the personalised panel design and depth sequencing, the assay serves particular identification and fragility of ctDNA directly from the plasma samples, delivering real-time insights into the responsive treatment and tumour dynamics.

With the MRD achieving milestones as the most considered solution to act as a monitoring tool for the response to the future designed therapies, the neogenomics introduction of RaDaR ST accelerates its presence as a collaborator to the biopharma companies looking for improved precision oncology. Alongside, the company will also highlight its vast range of oncology testing and the research potential of RaDaR ST at the #4012 booth.

Leaders’ statement

The chief executive officer, Tony Zook, said, “We stand strong by our dedication and promise to interventional studies and clinical validation using Neogenomics’ MRD technology, as shown in the 3 new posters from our European partners showcased at ESMO congress this year. We are thrilled to work consistently with our long-term contribution of interventional clinical trials and drug development, most recently with our RaDaR ST assay. The pharmaceutical sponsors are looking for partners who can serve operational and innovation excellence throughout every level of oncology trials. Neogenomics is an ideal choice that we were looking for RaDaR ST. The company has the potential to deliver patient-centric insights in real time to support accelerating the trial with more precise decisions and improved cancer research.”